Drug Prices
AHA today urged the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and 鈥渞eplace it with a serious effort at drug pricing reform.鈥�
AHA urges the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and 鈥渞eplace it with a serious effort at drug pricing reform.
AHA statement on court delay of most favored nation model interim final rule from Executive Vice President Tom Nickels.
Attorneys general in 27 states and Washington, D.C., today
The AHA filed a declaration supporting other organizations seeking a temporary restraining order and preliminary injunction to prevent the Centers for Medicare & Medicaid Services from cutting under its Most Favored Nation Model payments for certain Medicare Part B drugs and biologicals to no鈥�
The AHA filed a declaration supporting other organizations seeking a temporary restraining order and preliminary injunction to prevent the Centers for Medicare & Medicaid Services from cutting under its Most Favored Nation Model payments for certain Medicare Part B drugs and biologicals to no鈥�
The Centers for Medicare & Medicaid Services (CMS) Nov. 20 released an interim final rule implementing the Most Favored Nation (MFN) Model, a new payment model through the Center for Medicare and Medicaid Innovation (CMMI) that will cut Medicare Part B payments for certain drugs to the lowest鈥�
The Trump administration announced two actions that it claims will lower prescription drug prices.
Intermountain Healthcare has agreed to sell its Intalere group purchasing organization (formerly Amerinet) to Vizient, a GPO that also provides data analytics and performance-improvement insights to health systems.
Specialty drugs more than doubled as a share of retail fills for the overall U.S. population between 2010 and 2017, according to a study using various sources and published in Health Affairs, growing from 1% to 2.3%.